Industry Verticals »

All Categories

Insights »

About TMR »

RNA-Based Therapeutics Market

RNA-Based Therapeutics Market (By Therapeutic Type: mRNA Therapeutics, siRNA Therapeutics, RNA Aptamers and MicroRNAs, Others; By Application: Infectious Diseases, Oncology, Genetic & Rare Diseases, Neurological Disorders, Cardiovascular & Metabolic Diseases, Ophthalmic Disorders, Autoimmune & Inflammatory Diseases and Others; and by End-user: Hospitals & Clinics, Research & Academic Institutes and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2026–2036

RNA-Based Therapeutics Market Outlook 2036

The global RNA-Based Therapeutics market size was valued at USD 16.2 Billion in 2025 and is projected to reach USD 47.9 Billion by 2036, expanding at a CAGR of 10.4% from 2026 to 2036. The market is primarily driven by the rising prevalence of genetic, rare, infectious, and chronic diseases, coupled with increasing demand for highly targeted and personalized treatment approaches. Additionally, rapid advancements in RNA delivery technologies, growing clinical pipelines, increasing investments and strategic collaborations by pharmaceutical and biotechnology companies are accelerating market growth.

Market Size & Highlights

  • The RNA-based therapeutics market reached USD 16.2 Billion in 2025.
  • The market is expected to climb to USD 47.9 Billion by 2036.
  • The industry is anticipated to expand at a CAGR of 10.4% from 2026 to 2036.
  • The major players in the market include Alnylam Pharmaceuticals, BioNTech, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Sarepta Therapeutics, etc.
  • North America dominated the market in 2025, holding the largest revenue share of 38.3%
  • Infectious Diseases accounted for the largest market share of 31.8% in 2025

Rna Based Therapeutics Market By Revenue

Analysts’ Viewpoint

The advancement of RNA therapies and their different applications in the treatment of genetic disorders, infectious diseases, cancer, and chronic ailments is expected to drive the growth of the RNA-based therapeutic market over the forecast period along with increasing demand for precise and personalized medication. Key RNA therapeutic modalities include mRNA, siRNA, and antisense oligonucleotides, and there have also been extensive improvements in lipid nanoparticles used for delivering RNA. However, some challenges such as the unstable nature of RNA, off-target effects, and difficulties with delivering RNA to specific tissues, high costs, and strict regulations may hinder its success in the market.

The field of RNA therapy is evolving as the development of next-generation RNA medicines targeting various conditions, such as neurological, cardiovascular, metabolic, autoimmune, and oncology diseases. Increasing investments made by pharmaceutical and biotech corporations, more partnerships among companies, and a growing number of scientific collaborations are expected to accelerate RNA therapeutic development. The use of AI in RNA design, advanced bioinformatics, and new approaches to RNA delivery will help improve the outcomes of these projects. The trends observed in this market are connected with the move toward personalized RNA treatments, as well as the growth of self-amplifying RNA and circular RNA technologies.

Market Introduction

RNA therapeutics are medicines that use ribonucleic acid molecules to treat or prevent disease by influencing the flow of genetic information. Unlike traditional drugs that target proteins downstream, RNA therapies work upstream at the level of genetic messaging. RNA-based therapeutics utilize distinct mechanisms of action to target various biological pathways, offering innovative solutions for a range of diseases.

Attribute Detail
Market Drivers
  • Rising Prevalence of Genetic and Rare Diseases Driving Demand
  • Rapid Advancements in RNA Technologies and Targeted Delivery Platforms

Rising Prevalence of Genetic and Rare Diseases Driving Demand for Targeted RNA-Based Therapeutics Expected to Drive RNA-Based Therapeutics Market Size

The rising prevalence and improved diagnosis of genetic and rare disorders will drive the growth of the RNA-based therapeutics market. It is estimated that several rare diseases are connected to certain genetic mutations, necessitating the demand for therapies that can address pathological genes, RNA molecules, and molecular pathways responsible for the production of faulty proteins. Traditional therapeutic approaches available for several inherited diseases are still very limited, with the focus on alleviation of symptoms rather than elimination of the problem. RNA-based treatments, such as ASOs, siRNA, and mRNA therapies used for the direct modulation of gene expression and the ability to silence unwanted genes, control RNA splicing, and promote synthesis of important proteins.

Advances in genomic sequencing and molecular diagnostics are enabling the identification of genes responsible for diseases as well as expanding the population of patients who may benefit from precision treatment. The increasing clinical effectiveness of RNA therapeutics is encouraging pharmaceutical and biotech companies to increase confidence in RNA technologies. Several organizations are moving towards the development of RNA technologies.

Rapid Advancements in RNA Technologies and Targeted Delivery Platforms Accelerating Therapeutic Development and Commercialization Anticipated to Boost RNA-Based Therapeutics Market Expansion

The RNA-based therapeutics market is expected to expand significantly due to ongoing advancements in RNA technologies and targeted delivery systems. The ongoing development of messenger RNA (mRNA) technologies, small interfering RNA (siRNA), antisense oligonucleotides (ASOs), self-amplifying RNA and circular RNA continue to enhance the efficacy, safety and lifespan of RNA. Developments in both sequence optimization and chemical modifications are responsible for reducing the degradation of RNA and the undesired immune responses associated with RNA-based therapeutics.

In conjunction with this, the advancement of targeted RNA delivery systems has solved one of the key issues related to the delivery of RNA molecules to particular tissues and cells. Lipid nanoparticles (LNPs), GalNAc conjugates, polymer nanoparticles and ligand-targeted delivery systems are used to improve uptake by the cells, delivery to target tissues and bioavailability of therapeutic agents. This enables RNA drugs to go beyond the conventional approach of using them only for liver diseases and provide the solutions for treatment of cancers, neurological, cardiovascular, metabolic and inflammatory diseases. The improvements of RNA manufacturing and formulation processes are facilitating quicker development of clinical studies. The increase in the investments into novel delivery technologies and collaboration between pharmaceutical and biotechnology companies will further support continued innovation. Therefore, continued technological progress in RNA engineering and targeted delivery is expected to strengthen therapeutic pipelines, improve clinical outcomes, and accelerate the global commercialization of RNA-based therapeutics.

Attribute Detail
Market Opportunity
  • Increasing Strategic Collaborations and Licensing Agreements Accelerating RNA Therapeutic Pipeline Development

Increasing Strategic Collaborations and Licensing Agreements Accelerating RNA Therapeutic Pipeline Development

The increasing number of strategic alliances, licensing agreements, and research partnerships between pharmaceutical firms, biotechnology companies and research institutes provides significant opportunity for the growth for global RNA therapeutics market. The development of RNA-based drugs requires specific knowledge in the area of sequence development, RNA chemistry, delivery, production, and clinical development since such product development needs the unification of technologies. These agreements allow small biotechnology companies to benefit from the knowledge and experience of major pharmaceuticals.

The growing number of licensing agreements significantly contributes to the entrance into the market of new mRNA, siRNA, antisense oligonucleotide, and RNA delivery technologies. The common partnerships dedicated to lipid nanoparticles, GalNAc conjugates, and extrahepatic delivery systems also help in addressing the issue of targeted delivery of RNA-based drugs. Furthermore, partnerships in the area of research can help in decreasing innovation risks that any company can face while developing RNA drugs. Thus, due to these partnerships, the process of clinical trials of new RNA-based medications can be made quicker and, as a result, enhance the financing of the sector.

Infectious Diseases Driving RNA-Based Therapeutics Market Growth

Rna Based Therapeutics Market By Type

The infectious diseases segment dominated the RNA-based therapeutics market in 2025, accounting for approximately 31.8% of total market revenue. RNA technology has a number of advantages along with the fact that RNA technologies have been able to facilitate rapid sequence design, flexible manufacturing and the development of effective therapy candidate in relation to unknown infections. Because of these factors, the use of RNA technologies has become widespread in the field of infectious diseases.

Due to the success of mRNA vaccines, the confidence in RNA technologies has risen among pharmaceutical companies and healthcare professionals and the entire medical community. The increased amount of research in relation to viral diseases such as flu and cytomegalovirus has also widened the scope of RNA technologies. With the help of lipid-based delivery systems, RNA stabilization and flow design the efficiency and safety of RNA treatments has reached new heights. The increasing amount of funding, government support and cooperation for the development of vaccines and antivirals will promote the segment development. The increasing investment, technological advancement, and expanding infectious disease pipelines are expected to maintain the segment's leading position in the global RNA-based therapeutics market.

Regional Outlook of RNA-Based Therapeutics Market

Rna Based Therapeutics Market By Region

Attribute Detail
Leading Region
  • North America

North America dominated the global RNA-based therapeutics market in 2025, accounting for approximately 38.3% of total market revenue. The North America region dominates the global RNA-based therapeutics market. This is attributed to the increasing investments in the RNA sector, strong presence of established biotech and pharmaceutical industry actors, and rapid uptake of cutting-edge therapeutic technologies. The region is host to some of the most significant RNA therapeutics companies in addition to budding biotechnology enterprises involved in the development of mRNA, siRNA, antisense oligonucleotide, and other analogs of next-generation RNA. The development and commercialization of RNA therapies is also aided by the existence of robust clinical research infrastructure and increasing funding levels directed towards precision medicine.

In addition, the increasing prevalence of cancer as well as genetic diseases, rare diseases, neurological disorders, and cardiovascular and metabolic disorders is triggering growth in demand for targeted therapies in North America. Strong funding from both public sector agencies as well as private investors coupled with an increase in the number of collaborations of pharmaceutical companies with biotechnology enterprises and academic research institutions is accelerating development of RNA therapies. The presence of advanced manufacturing capabilities and an established regulatory framework also supports the translation of clinical research into commercial applications.

Analysis of Key Players in RNA-Based Therapeutics Market

Alnylam Pharmaceuticals, Inc., BioNTech SE, Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Silence Therapeutics, CRISPR Therapeutics, Pfizer Inc., Novartis AG, AstraZeneca, Sanofi, GSK plc., Regeneron Pharmaceuticals Inc., Wave Life Sciences, Sirnaomics, Inc., Arbutus Biopharma, Intellia Therapeutics Inc., Strand Therapeutics and Other prominent players are among the key players operating in the global RNA-based therapeutics market.

Each of these players has been profiled in the RNA-Based Therapeutics market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments

  • In February 2026, Ethris GmbH and the German Center for Infection Research announced a strategic research collaboration to develop mRNA-based vaccines for the prevention and treatment of infectious diseases. The collaboration combines Ethris’ proprietary, clinically-validated mRNA technology platforms with DZIF’s translational vaccine research expertise spanning a broad spectrum of pathogens, including viruses, bacteria, and parasites.
  • In June 2026, Ionis Pharmaceuticals, Inc. announced that it has entered into a license agreement with Recordati, under which Recordati obtained exclusive rights to develop and commercialize zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), in all countries outside the U.S. Ionis will maintain sole commercial responsibility for zilganersen in the U.S. and will continue to lead development globally. Recordati will be responsible for regulatory filings and commercialization outside the U.S., including country-specific support for early access pathways based on local regulations and access dynamics.
  • In November 2025, Arrowhead Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease, with an estimated 6,500 people in the U.S. living with genetic or clinical FCS, characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potentially fatal pancreatitis.

RNA-Based Therapeutics Market Snapshot

Attribute Detail
Size in 2025 USD 16.2 Billion
Forecast Value in 2036 USD 47.9 Billion
CAGR 10.4%
Forecast Period 2026-2036
Historical Data Available for 2021-2025
Quantitative Units USD Billion for Value
Market Analysis It includes segment analysis as well as regional level analysis. Qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape
  • Competition Matrix
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Segmentation By Therapeutic Type
  • Messenger RNA (mRNA) Therapeutics
  • Small Interfering RNA (siRNA) Therapeutics
  • RNA Aptamers and MicroRNAs
  • Other RNA-Based Therapeutics (saRNA, circRNA, RNA editing, ribozymes)
By Application
  • Infectious Diseases
  • Oncology
  • Genetic & Rare Diseases
  • Neurological Disorders
  • Cardiovascular & Metabolic Diseases
  • Ophthalmic Disorders
  • Autoimmune & Inflammatory Diseases
  • Others
By End-user
  • Hospitals & Clinics
  • Research & Academic Institutes
  • Others
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • The Netherlands
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • ASEAN
  • Brazil
  • Mexico
  • Argentina
  • GCC Countries
  • South Africa
Companies Profiled
  • Alnylam Pharmaceuticals, Inc.
  • BioNTech SE
  • Ionis Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics
  • CRISPR Therapeutics
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca
  • Sanofi
  • GSK plc.
  • Regeneron Pharmaceuticals Inc.
  • Wave Life Sciences
  • Sirnaomics, Inc.
  • Arbutus Biopharma
  • Intellia Therapeutics Inc.
  • Strand Therapeutics
  • Other Prominent Players
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global RNA-based therapeutics market in 2025?

The market was valued at USD 16.2 Billion in 2025

What is the projected size of the RNA-based therapeutics market by 2036?

The market is projected to reach USD 47.9 billion by 2036

What are the factors driving the RNA-based therapeutics market?

Rising prevalence of genetic and rare diseases and rapid advancements in RNA technologies and targeted delivery platforms.

At what CAGR is the RNA-based therapeutics market expected to grow during the forecast period?

The market is anticipated to expand at a CAGR of 10.4% from 2026 to 2036

Which region is expected to dominate the RNA-based therapeutics market during the forecast period?

North America is expected to account for the largest market share from 2026 to 2036

Who are the prominent RNA-based therapeutics providers?

Alnylam Pharmaceuticals, Inc., BioNTech SE, Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Silence Therapeutics, CRISPR Therapeutics, Pfizer Inc., Novartis AG, AstraZeneca, Sanofi, GSK plc., Regeneron Pharmaceuticals Inc., Wave Life Sciences, Sirnaomics, Inc., Arbutus Biopharma, Intellia Therapeutics Inc., and Strand Therapeutics, among others.

  1. Preface
    • Market Definition and Scope
    • Market Segmentation
    • Key Research Objectives
    • Research Highlights
  2. Assumptions and Research Methodology
  3. Executive Summary: Global RNA-Based Therapeutics Market
  4. Market Overview
    • Introduction
      • Segment Definition
    • Overview
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunities
    • Global RNA-Based Therapeutics Market Analysis and Forecast, 2021-2036
      • Market Revenue Projections (USD Billion)
  5. Key Insights
    • Regulatory Approvals and Commercialization Analysis
    • Clinical Pipeline Analysis
    • RNA Delivery Technology Advancements
    • Patent Landscape Analysis
    • Strategic Collaborations and Licensing Analysis
    • Pricing and Reimbursement Analysis
    • Emerging RNA Modality Analysis
    • PESTLE Analysis
    • Porter’s Five Forces Analysis
    • Healthcare Expenditure by Country/Region
  6. Global RNA-Based Therapeutics Market Analysis and Forecast, by Therapeutic Type
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Attractiveness Analysis, by Therapeutic Type
  7. Global RNA-Based Therapeutics Market Analysis and Forecast, by Application
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Attractiveness Analysis, by Application
  8. Global RNA-Based Therapeutics Market Analysis and Forecast, by End-user
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis, by End-user
  9. Global RNA-Based Therapeutics Market Analysis and Forecast, by Region
    • Key Findings
    • Market Value Forecast, by Region, 2021-2036
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa
    • Market Attractiveness Analysis, by Region
  10. North America RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • U.S.
      • Canada
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
      • By Country/Sub-region
  11. U.S. RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  12. Canada RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  13. Europe RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • The Netherlands
      • Switzerland
      • Rest of Europe
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
      • By Country/Sub-region
  14. Germany RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  15. U.K. RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  16. France RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  17. Italy RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  18. Spain RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  19. The Netherlands RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  20. Switzerland RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  21. Rest of Europe RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  22. Asia Pacific RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • China
      • India
      • Japan
      • South Korea
      • Australia and New Zealand
      • Rest of Asia Pacific
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
      • By Country/Sub-region
  23. China RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  24. India RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  25. Japan RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  26. South Korea RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  27. Australia and New Zealand RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  28. Rest of Asia Pacific RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  29. Latin America RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
      • By Country/Sub-region
  30. Brazil RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  31. Mexico RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  32. Argentina RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  33. Rest of Latin America RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  34. Middle East & Africa RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
      • By Country/Sub-region
  35. GCC Countries RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  36. South Africa RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  37. Rest of Middle East & Africa RNA-Based Therapeutics Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Therapeutic Type, 2021-2036
      • Messenger RNA (mRNA) Therapeutics
      • Small Interfering RNA (siRNA) Therapeutics
      • RNA Aptamers and MicroRNAs
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Infectious Diseases
      • Oncology
      • Genetic & Rare Diseases
      • Neurological Disorders
      • Cardiovascular & Metabolic Diseases
      • Ophthalmic Disorders
      • Autoimmune & Inflammatory Diseases
      • Others
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Others
    • Market Attractiveness Analysis
      • By Therapeutic Type
      • By Application
      • By End-user
  38. Competition Landscape
    • Market Player - Competition Matrix (By Tier and Size of Companies)
    • Market Share Analysis, by Company (2024)
    • Company Profiles
      • Alnylam Pharmaceuticals, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • BioNTech SE
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Ionis Pharmaceuticals, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Arrowhead Pharmaceuticals, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Sarepta Therapeutics, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Silence Therapeutics
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • CRISPR Therapeutics
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Pfizer Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Novartis AG
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • AstraZeneca
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Sanofi
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • GSK plc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Regeneron Pharmaceuticals Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Wave Life Sciences
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Sirnaomics, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Arbutus Biopharma
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Intellia Therapeutics Inc
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Strand Therapeutics
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Other Prominent Players
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments

List of Tables

Table 01: Global RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 02: Global RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 03: Global RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 04: Global RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 05: North America RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 06: North America RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 07: North America RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 08: North America RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 09: U.S. RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 10: U.S. RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 11: U.S. RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 12: Canada RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 13: Canada RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 14: Canada RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 15: Europe RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 16: Europe RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 17: Europe RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 18: Europe RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 19: Germany RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 20: Germany RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 21: Germany RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 22: U.K. RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 23: U.K. RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 24: U.K. RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 25: France RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 26: France RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 27: France RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 28: Italy RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 29: Italy RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 30: Italy RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 31: Spain RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 32: Spain RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 33: Spain RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 34: Switzerland RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 35: Switzerland RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 36: Switzerland RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 37: The Netherlands RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 38: The Netherlands RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 39: The Netherlands RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 40: Rest of Europe RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 41: Rest of Europe RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 42: Rest of Europe RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 43: Asia Pacific RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 44: Asia Pacific RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 45: Asia Pacific RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 46: Asia Pacific RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 47: China RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 48: China RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 49: China RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 50: Japan RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 51: Japan RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 52: Japan RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 53: India RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 54: India RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 55: India RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 56: South Korea RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 57: South Korea RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 58: South Korea RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 59: Australia and New Zealand RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 60: Australia and New Zealand RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 61: Australia and New Zealand RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 62: Rest of Asia Pacific RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 63: Rest of Asia Pacific RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 64: Rest of Asia Pacific RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 65: Latin America RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 66: Latin America RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 67: Latin America RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 68: Latin America RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 69: Brazil RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 70: Brazil RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 71: Brazil RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 72: Mexico RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 73: Mexico RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 74: Mexico RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 75: Argentina RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 76: Argentina RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 77: Argentina RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 78: Rest of Latin America RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 79: Rest of Latin America RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 80: Rest of Latin America RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 81: Middle East and Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 82: Middle East and Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 83: Middle East and Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 84: Middle East and Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 85: GCC Countries RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 86: GCC Countries RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 87: GCC Countries RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 88: South Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 89: South Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 90: South Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 91: Rest of Middle East and Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Therapeutic Type, 2021 to 2036
Table 92: Rest of Middle East and Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 93: Rest of Middle East and Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, by End-user, 2021 to 2036

List of Figures

Figure 01: Global RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 02: Global RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 03: Global RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 04: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Messenger RNA (mRNA) Therapeutics, 2021 to 2036
Figure 05: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Small Interfering RNA (siRNA) Therapeutics, 2021 to 2036
Figure 06: Global RNA-Based Therapeutics Market Revenue (USD Billion), by RNA Aptamers and MicroRNAs, 2021 to 2036
Figure 07: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Others, 2021 to 2036
Figure 08: Global RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 09: Global RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 10: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Infectious Diseases, 2021 to 2036
Figure 11: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Oncology, 2021 to 2036
Figure 12: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Genetic & Rare Diseases, 2021 to 2036
Figure 13: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Neurological Disorders, 2021 to 2036
Figure 14: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Cardiovascular & Metabolic Diseases, 2021 to 2036
Figure 15: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Ophthalmic Disorders, 2021 to 2036
Figure 16: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Autoimmune & Inflammatory Diseases, 2021 to 2036
Figure 17: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Others, 2021 to 2036
Figure 18: Global RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 19: Global RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 20: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Hospitals & Clinics, 2021 to 2036
Figure 21: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Research & Academic Institutes, 2021 to 2036
Figure 22: Global RNA-Based Therapeutics Market Revenue (USD Billion), by Others, 2021 to 2036
Figure 23: Global RNA-Based Therapeutics Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 24: Global RNA-Based Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 25: North America RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 26: North America RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 27: North America RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 28: North America RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 29: North America RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 30: North America RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 31: North America RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 32: North America RNA-Based Therapeutics Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 33: North America RNA-Based Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 34: U.S. RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 35: U.S. RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 36: U.S. RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 37: U.S. RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 38: U.S. RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 39: U.S. RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 40: U.S. RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 41: Canada RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 42: Canada RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 43: Canada RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 44: Canada RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 45: Canada RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 46: Canada RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 47: Canada RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 48: Europe RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 49: Europe RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 50: Europe RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 51: Europe RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 52: Europe RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 53: Europe RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 54: Europe RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 55: Europe RNA-Based Therapeutics Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 56: Europe RNA-Based Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 57: Germany RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 58: Germany RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 59: Germany RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 60: Germany RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 61: Germany RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 62: Germany RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 63: Germany RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 64: U.K. RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 65: U.K. RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 66: U.K. RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 67: U.K. RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 68: U.K. RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 69: U.K. RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 70: U.K. RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 71: France RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 72: France RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 73: France RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 74: France RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 75: France RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 76: France RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 77: France RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 78: Italy RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 79: Italy RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 80: Italy RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 81: Italy RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 82: Italy RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 83: Italy RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 84: Italy RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 85: Spain RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 86: Spain RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 87: Spain RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 88: Spain RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 89: Spain RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 90: Spain RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 91: Spain RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 92: Switzerland RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 93: Switzerland RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 94: Switzerland RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 95: Switzerland RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 96: Switzerland RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 97: Switzerland RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 98: Switzerland RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 99: The Netherlands RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 100: The Netherlands RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 101: The Netherlands RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 102: The Netherlands RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 103: The Netherlands RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 104: The Netherlands RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 105: The Netherlands RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 106: Rest of Europe RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 107: Rest of Europe RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 108: Rest of Europe RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 109: Rest of Europe RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 110: Rest of Europe RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 111: Rest of Europe RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 112: Rest of Europe RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 113: Asia Pacific RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 114: Asia Pacific RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 115: Asia Pacific RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 116: Asia Pacific RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 117: Asia Pacific RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 118: Asia Pacific RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 119: Asia Pacific RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 120: Asia Pacific RNA-Based Therapeutics Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 121: Asia Pacific RNA-Based Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 122: China RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 123: China RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 124: China RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 125: China RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 126: China RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 127: China RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 128: China RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 129: Japan RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 130: Japan RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 131: Japan RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 132: Japan RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 133: Japan RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 134: Japan RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 135: Japan RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 136: India RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 137: India RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 138: India RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 139: India RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 140: India RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 141: India RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 142: India RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 143: South Korea RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 144: South Korea RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 145: South Korea RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 146: South Korea RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 147: South Korea RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 148: South Korea RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 149: South Korea RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 150: Australia and New Zealand RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 151: Australia and New Zealand RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 152: Australia and New Zealand RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 153: Australia and New Zealand RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 154: Australia and New Zealand RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 155: Australia and New Zealand RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 156: Australia and New Zealand RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 157: Rest of Asia Pacific RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 158: Rest of Asia Pacific RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 159: Rest of Asia Pacific RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 160: Rest of Asia Pacific RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 161: Rest of Asia Pacific RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 162: Rest of Asia Pacific RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 163: Rest of Asia Pacific RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 164: Latin America RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 165: Latin America RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 166: Latin America RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 167: Latin America RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 168: Latin America RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 169: Latin America RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 170: Latin America RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 171: Latin America RNA-Based Therapeutics Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 172: Latin America RNA-Based Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 173: Brazil RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 174: Brazil RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 175: Brazil RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 176: Brazil RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 177: Brazil RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 178: Brazil RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 179: Brazil RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 180: Mexico RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 181: Mexico RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 182: Mexico RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 183: Mexico RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 184: Mexico RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 185: Mexico RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 186: Mexico RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 187: Argentina RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 188: Argentina RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 189: Argentina RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 190: Argentina RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 191: Argentina RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 192: Argentina RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 193: Argentina RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 194: Rest of Latin America RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 195: Rest of Latin America RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 196: Rest of Latin America RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 197: Rest of Latin America RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 198: Rest of Latin America RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 199: Rest of Latin America RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 200: Rest of Latin America RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 201: Middle East and Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 202: Middle East and Africa RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 203: Middle East and Africa RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 204: Middle East and Africa RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 205: Middle East and Africa RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 206: Middle East and Africa RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 207: Middle East and Africa RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 208: Middle East and Africa RNA-Based Therapeutics Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 209: Middle East and Africa RNA-Based Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 210: GCC Countries RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 211: GCC Countries RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 212: GCC Countries RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 213: GCC Countries RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 214: GCC Countries RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 215: GCC Countries RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 216: GCC Countries RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 217: South Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 218: South Africa RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 219: South Africa RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 220: South Africa RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 221: South Africa RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 222: South Africa RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 223: South Africa RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 224: Rest of Middle East and Africa RNA-Based Therapeutics Market Value (USD Billion) Forecast, 2021 to 2036
Figure 225: Rest of Middle East and Africa RNA-Based Therapeutics Market Value Share Analysis, by Therapeutic Type, 2025 and 2036
Figure 226: Rest of Middle East and Africa RNA-Based Therapeutics Market Attractiveness Analysis, by Therapeutic Type, 2026 to 2036
Figure 227: Rest of Middle East and Africa RNA-Based Therapeutics Market Value Share Analysis, by Application, 2025 and 2036
Figure 228: Rest of Middle East and Africa RNA-Based Therapeutics Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 229: Rest of Middle East and Africa RNA-Based Therapeutics Market Value Share Analysis, by End-user, 2025 and 2036
Figure 230: Rest of Middle East and Africa RNA-Based Therapeutics Market Attractiveness Analysis, by End-user, 2026 to 2036

Copyright © Transparency Market Research, Inc. All Rights reserved

RNA-Based Therapeutics Market

Buy This ReportBuy Now